Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Mar 29, 2025
Product Development
Bispecifics for I&I: Bypassing combination complexity
At least 30 companies have bispecific antibodies in development for autoimmune and inflammatory diseases
BioCentury | Jan 18, 2025
Product Development
2025 catalysts: New I&I indications take center stage
Inflammation and immunology readouts to define new priority indications, modality opportunities in immune reset
BioCentury | Aug 14, 2024
Product Development
Clinical Report: Acelyrin shifts priorities; Rivus moving forward in obesity
Plus: Readouts from Avidity, Apellis/Sobi, Levicept and Merck
BioCentury | Apr 6, 2024
Finance
Public equity report: Contineum’s NASDAQ listing, Oruka’s financing-merger combo
Plus: Surrozen and Sutro raise cash, and Redx proposes to delist from London’s AIM
BioCentury | Mar 23, 2024
Data Byte
EMA’s CHMP backs approval of Novartis’ complement drug
March decisions also include label extensions for UCB’s Bimzelx and Astellas’ Xtandi. Takeda pulls an application for Adcetris
BioCentury | Mar 12, 2024
Product Development
Clinical report: takeaways from Amylyx’s ALS journey
Plus: A comeback for Regulus? And updates from Acadia, MoonLake, Ventyx, Acelyrin, Sanofi and more
BioCentury | Dec 11, 2023
Product Development
Building on dermatology’s recent success
Targets, mechanisms and indications that stand to benefit from the surging interest in dermatology
BioCentury | Nov 6, 2023
Deals
Nov. 6 Quick Takes: BMS buying Orum’s protein degrader
Plus: Ventyx terminates VTX958 in plaque psoriasis, psoriatic arthritis and updates from Celldex, MoonLake and ProfoundBio
BioCentury | Oct 19, 2023
Regulation
Oct. 18 Quick Takes: FDA approves UCB’s Bimzelx and Zilbrysq
Plus: After appeal, Ardelyx wins approval of kidney therapy, and updates from Mablink, Actym, Syncona, CDER and more
BioCentury | Jul 31, 2023
Finance
China Venture Quick Takes: Pyrotech raises $97M series A
Plus: Series B round for immunology company Xinkanghe, and updates from Migrasome, Immuno Cure and Forward
Items per page:
1 - 10 of 45